Reactivity to type I interferon is key to predict cancer immunotherapy response View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-07-25

ABSTRACT

The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.

PAGES

1146-1147

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z

DOI

http://dx.doi.org/10.1038/s41590-022-01278-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149723766

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35879452


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon Type I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/s41590-021-00975-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1139927264", 
          "https://doi.org/10.1038/s41590-021-00975-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-07-25", 
    "datePublishedReg": "2022-07-25", 
    "description": "The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41590-022-01278-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1022778", 
        "issn": [
          "1529-2908", 
          "1529-2916"
        ], 
        "name": "Nature Immunology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "effector CD4 T cells", 
      "cancer immunotherapy response", 
      "immune checkpoint inhibition", 
      "CD4 T cells", 
      "overall survival", 
      "treatment initiation", 
      "checkpoint inhibition", 
      "immunotherapy response", 
      "T cells", 
      "I interferon", 
      "therapeutic efficacy", 
      "patients", 
      "interferon", 
      "cancer", 
      "response", 
      "efficacy", 
      "survival", 
      "responsiveness", 
      "inhibition", 
      "cells", 
      "initiation", 
      "reactivity", 
      "features", 
      "relevant features", 
      "deterministic"
    ], 
    "name": "Reactivity to type I interferon is key to predict cancer immunotherapy response", 
    "pagination": "1146-1147", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149723766"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41590-022-01278-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35879452"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41590-022-01278-z", 
      "https://app.dimensions.ai/details/publication/pub.1149723766"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:44", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_928.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41590-022-01278-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41590-022-01278-z'


 

This table displays all metadata directly associated to this object as RDF triples.

99 TRIPLES      20 PREDICATES      55 URIs      45 LITERALS      10 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41590-022-01278-z schema:about N0384d59dcc444b2c82863d618850b669
2 N785c9cbedf9f4c89b4dd127b98c42347
3 Na6c3ca75f6274af1a30fd28f09cc13a3
4 Ncf946208f35d41559a4f19dbde361c55
5 anzsrc-for:11
6 anzsrc-for:1107
7 anzsrc-for:1112
8 schema:citation sg:pub.10.1038/s41590-021-00975-5
9 schema:datePublished 2022-07-25
10 schema:datePublishedReg 2022-07-25
11 schema:description The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.
12 schema:genre article
13 schema:isAccessibleForFree false
14 schema:isPartOf N8390c17b535e4d328a2de784406e48c0
15 N86c1645eb48e4988b9579f9474e4f6b3
16 sg:journal.1022778
17 schema:keywords CD4 T cells
18 I interferon
19 T cells
20 cancer
21 cancer immunotherapy response
22 cells
23 checkpoint inhibition
24 deterministic
25 effector CD4 T cells
26 efficacy
27 features
28 immune checkpoint inhibition
29 immunotherapy response
30 inhibition
31 initiation
32 interferon
33 overall survival
34 patients
35 reactivity
36 relevant features
37 response
38 responsiveness
39 survival
40 therapeutic efficacy
41 treatment initiation
42 schema:name Reactivity to type I interferon is key to predict cancer immunotherapy response
43 schema:pagination 1146-1147
44 schema:productId N507856203a804d99a4b298c38b0e706c
45 N89cb5b0e90af4894a8a417a7c47f45b2
46 Ncef40d66e41f48808381ba0d04f71eba
47 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149723766
48 https://doi.org/10.1038/s41590-022-01278-z
49 schema:sdDatePublished 2022-12-01T06:44
50 schema:sdLicense https://scigraph.springernature.com/explorer/license/
51 schema:sdPublisher N1418ecdcbb1e436b9573c869dabba4c3
52 schema:url https://doi.org/10.1038/s41590-022-01278-z
53 sgo:license sg:explorer/license/
54 sgo:sdDataset articles
55 rdf:type schema:ScholarlyArticle
56 N0384d59dcc444b2c82863d618850b669 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Interferon Type I
58 rdf:type schema:DefinedTerm
59 N1418ecdcbb1e436b9573c869dabba4c3 schema:name Springer Nature - SN SciGraph project
60 rdf:type schema:Organization
61 N507856203a804d99a4b298c38b0e706c schema:name pubmed_id
62 schema:value 35879452
63 rdf:type schema:PropertyValue
64 N785c9cbedf9f4c89b4dd127b98c42347 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Immunotherapy
66 rdf:type schema:DefinedTerm
67 N8390c17b535e4d328a2de784406e48c0 schema:issueNumber 8
68 rdf:type schema:PublicationIssue
69 N86c1645eb48e4988b9579f9474e4f6b3 schema:volumeNumber 23
70 rdf:type schema:PublicationVolume
71 N89cb5b0e90af4894a8a417a7c47f45b2 schema:name dimensions_id
72 schema:value pub.1149723766
73 rdf:type schema:PropertyValue
74 Na6c3ca75f6274af1a30fd28f09cc13a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Humans
76 rdf:type schema:DefinedTerm
77 Ncef40d66e41f48808381ba0d04f71eba schema:name doi
78 schema:value 10.1038/s41590-022-01278-z
79 rdf:type schema:PropertyValue
80 Ncf946208f35d41559a4f19dbde361c55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Neoplasms
82 rdf:type schema:DefinedTerm
83 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
84 schema:name Medical and Health Sciences
85 rdf:type schema:DefinedTerm
86 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
87 schema:name Immunology
88 rdf:type schema:DefinedTerm
89 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
90 schema:name Oncology and Carcinogenesis
91 rdf:type schema:DefinedTerm
92 sg:journal.1022778 schema:issn 1529-2908
93 1529-2916
94 schema:name Nature Immunology
95 schema:publisher Springer Nature
96 rdf:type schema:Periodical
97 sg:pub.10.1038/s41590-021-00975-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139927264
98 https://doi.org/10.1038/s41590-021-00975-5
99 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...